Unlocking the Value of Biodiversity in the UK and Ireland
Sequencing the DNA of all complex life in the UK and Ireland, the Darwin Tree of Life (DToL) project plans to generate reference genomes for 30,000 eukaryotic species. A Frontier Economics report estimates the initiative could deliver up to $3.8 bn of economic benefit over the next 30 years through gains in agriculture, medicine and conservation. To date, the open‑access dataset has saved the global research community roughly $70 m by providing more than 2,500 reference genomes. The effort is coordinated by EMBL‑EBI, the Wellcome Sanger Institute and a broad network of academic and conservation partners.
Boehringer Ingelheim and Zai Lab Team up for Dual DLL3 Therapy Study
Boehringer Ingelheim and Zai Lab have launched a Phase Ib/II trial that pairs Boehringer’s DLL3‑directed T‑cell engager obrixtamig with Zai Lab’s DLL3‑targeting ADC zoci. The study will evaluate safety, tolerability and early efficacy in patients with extensive‑stage small‑cell lung cancer and other neuroendocrine...
Freya Biosciences Advances Microbial Treatment for IVF Implantation Failure
Freya Biosciences announced that its microbial immunotherapy designed to address IVF implantation failure has progressed to a Phase 2 mid‑stage trial after demonstrating safety and early efficacy in healthy volunteers. The therapy leverages modulation of the uterine microbiome to improve endometrial...
AOP Health Reports the US FDA Approval Rapiblyk (Landiolol) for Pediatric Patients with Supraventricular Tachycardia
The U.S. Food and Drug Administration has granted approval for Rapiblyk (landiolol) for pediatric patients from birth through 17 years old suffering from supraventricular tachycardia (SVT). The decision follows the LANDI‑PED trial, which enrolled 60 children and demonstrated a greater...
TLR7 Signature Uncovers Two Triple-Negative Breast Cancer Paths
A new multi‑institutional study identified a TLR7‑based gene signature that separates triple‑negative breast cancer (TNBC) into two biologically distinct pathways. Analysis of 312 tumor samples revealed that high TLR7 expression defines an immunogenic subtype with better prognosis, while low TLR7...
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
Chinese biopharma Mabwell announced that the National Medical Products Administration has accepted a supplemental biologics license application for MAIWEIJIAN, its denosumab biosimilar. The 120 mg injection, already approved in China for giant cell tumor of bone and in Pakistan, is now...
Effect of ‘Gamechanger’ Alzheimer’s Drugs ‘Trivial’, Review Concludes
A new Cochrane Review of 17 clinical trials involving more than 20,000 participants found that anti‑amyloid drugs—including lecanemab and donanemab—produce only trivial cognitive benefits and modest functional gains over 18 months. The analysis also highlighted a higher incidence of brain...
Enhancing Antitumour Nanovaccine Efficacy via Integrated Cholesterol Modulation in Situ
Researchers have created a nanovaccine, NPCM‑OT, that simultaneously delivers tumor antigens and depletes cholesterol from dendritic cell membranes. The cholesterol reduction reshapes lipid microdomains, enhancing immune‑synapse formation and CD8⁺ T‑cell activation. In multiple mouse tumor models, the vaccine showed both...
GLP-1s Don't Work for Everyone: Why, and What to Do?
GLP‑1 receptor agonists have become a cornerstone of modern weight‑loss therapy, yet roughly 20% of patients fail to achieve meaningful reductions. A recent review proposes pairing a GLP‑1 drug with the naltrexone‑bupropion combo (Contrave) to address this gap, leveraging complementary...
Single Blood Sample Could Soon Screen for Several Cancers, Study Suggests
UCLA researchers unveiled MethylScan, a low‑cost blood test that reads DNA methylation patterns in cell‑free DNA to flag multiple cancers and liver diseases from a single draw. By stripping out 80‑90% of background DNA, the assay slashes sequencing needs, driving...
Color Test 'Sniffs Out' Dangerous Staph Strains Fast
Researchers at RMIT University have created a rapid, low‑cost color‑changing test that distinguishes virulent and antibiotic‑resistant Staphylococcus aureus strains. The assay uses gold nanozyme particles and DNA aptamer binders to generate strain‑specific color fingerprints, functioning effectively in simulated wound fluid....
Spain Plants US$200m Flag in Boston with Debut US Biotech Fund
Spain has unveiled a $200 million venture‑capital fund based in Boston, anchored by $57 million of public seed capital. The fund will back Spanish life‑science startups seeking to scale within the U.S. ecosystem and co‑invest in select American biotech firms. A new...
Fujifilm Biotechnologies Opens New QC Lab in Denmark
Fujifilm Biotechnologies has opened a 2,000‑square‑meter GMP‑approved quality control laboratory at its Hillerød, Denmark site. The facility, designed for bioassay and virology work, will accommodate roughly 100 quality‑team members and features robotics, airlocks and a new LIMS for digital data...
Real-World Evoque Data Reassure, but It’s Still Early Days With TTVR
Early US real‑world data from the TVT Registry show that transcatheter tricuspid valve replacement (TTVR) with Edwards' Evoque device matches or modestly exceeds outcomes from the pivotal TRISCEND II trial. In 1,034 patients (average age 77, 69% female) 30‑day mortality was...
New Drug Protects Against Life-Threatening Pancreatitis
A new RNA‑based drug, plozasiran, received its first clinical validation for a rare inherited disorder that causes extreme blood‑fat accumulation and recurrent acute pancreatitis. In the PALISADE trial, a single injection every three months lowered the risk of pancreatitis by...
CRISPR Variant Selectively Targets Tumor DNA
Researchers at Van Andel Institute and Wageningen University have engineered a CRISPR variant, ThermoCas9, that reads DNA methylation patterns to differentiate tumor DNA from healthy DNA. The enzyme selectively cuts methylated cancer sequences while sparing unmethylated normal genes, a finding published...
Rapid Melatonin Test Can Help Astronauts and Others Easily Monitor Their Biological Rhythm
Washington State University researchers have created a 15‑minute melatonin test that combines a paper‑strip assay with a 3D‑printed smartphone fluorescence reader. The lateral‑flow immunoassay uses europium nanoparticles to achieve laboratory‑grade sensitivity of 10 picograms per milliliter, pinpointing the onset of an...
InSPECt™ MS – Global HCP Profiling and Quantification by Native Digestion and LC-MS Analysis
The inSPECt™ MS platform combines native digestion with high‑resolution LC‑MS to quantify host‑cell proteins (HCPs) relative to spiked‑in protein standards. Calibration using the Cygnus Protein Standard demonstrated a linear response from 10 to 500 ppm with coefficients of variation under 18 %...
Vitamin C Alleviates Aging in Cynomolgus Monkeys
Researchers introduced the term “ferro‑aging” to describe iron‑driven lipid peroxidation that accelerates cellular senescence. They showed that excess iron elevates ACSL4, boosting reactive oxygen species and aging markers in cells, mice and cynomolgus monkeys. A high‑throughput screen identified vitamin C as...
Digital Twin Process Could Slash Microbial Protein Costs
A consortium led by Novasign has built an end‑to‑end digital twin of the microbial protein production process, promising to cut experimental runs by roughly 70% compared with traditional design‑of‑experiments approaches. The model spans upstream to downstream steps, offering real‑time deviation...
Ultra- and Diafiltration Clear Leachables Effectively
A new study from the National Institute for Bioprocessing Research demonstrates that ultrafiltration and diafiltration (UF/DF) consistently remove over 98% of 24 out of 28 tested leachable compounds across three distinct protein processes. The clearance is largely driven by the...
IPSC-Based Manufacture Vs. Autologous Model Production Costs Examined via Financial Analysis
A new Cellistic white paper quantifies the cost advantage of using induced pluripotent stem cells (iPSCs) to manufacture NK cell therapies. The analysis shows cost of goods per dose can drop to roughly $5,000, a 95% reduction compared with $115,000...
Biopharma Adopting AI Despite Remaining GMP Compliance Questions
Biopharma firms are rapidly integrating artificial intelligence and machine learning into manufacturing, but regulatory‑compliant use cases remain a hurdle. Thermo Fisher’s senior director emphasizes that AI should augment, not replace, validated processes and must operate within a clear GMP framework....
This Pill May Help Pancreatic Cancer Patients Live Longer
Revolution Medicines announced that its RAS‑blocking pill daraxonrasib more than doubled median overall survival for patients with metastatic pancreatic cancer, extending it to 13.2 months versus 6.7 months on chemotherapy. The data will support an expedited FDA filing, and the...
In Vivo Autoimmune CAR-T Race Grows as Two RNA Startups Enter the Clinic
Two RNA‑focused biotech firms have entered human trials of in vivo CAR‑T therapies targeting autoimmune diseases. China’s Immorna reported its first systemic sclerosis patient treated with an RNA‑delivered CAR‑T that reduced peripheral B‑cell activity. A U.S. startup, GeneCure, launched a...
US FDA to Convene Expert Panel to Review Wider Access to some Peptides
The U.S. Food and Drug Administration announced it will convene an external advisory panel in July to decide whether licensed compounding pharmacies can resume manufacturing more than half a dozen peptides that were barred in 2023. The ban covered 14...
Former FDA Cancer Chief Pazdur Warns of the Political 'Breach' Of Review Teams
Richard Pazdur, who led the FDA’s oncology review program for more than two decades, stepped down in December after only a few weeks as director of the agency’s Center for Drug Evaluation and Research. In his departure, Pazdur warned that...
Novel Targets for Complex Cancer Revealed by Genetic Regulatory Node Mapping
Researchers at Rockefeller University unveiled PerturbFate, a single‑cell platform that maps how diverse genetic variations reshape cellular behavior over time. By profiling DNA accessibility, RNA output, and chromatin state in thousands of cells, the system identified common regulatory nodes that...
Revolution Medicines Prices $2B Raise as XBI Reaches Heights Not Seen Since Pandemic
Revolution Medicines priced a $2 billion public offering, marking the biotech sector’s largest equity raise since the COVID‑19 pandemic. The capital raise follows a recent positive readout from the company’s late‑stage trial, boosting investor confidence. The move helped lift the SPDR...
What’s the Deal with Alzheimer’s Disease and Amyloid?
A wave of retractions, including a 2011 Neurobiology of Aging paper, has exposed fabricated data behind the amyloid‑β hypothesis for Alzheimer’s disease. Decades of costly clinical trials targeting amyloid‑β have repeatedly failed to deliver meaningful cognitive benefits, culminating in the...
BIO Launches ‘Fight of Our Lives’: The Real Stories, Power, and Promise of American Biotech at a Defining Moment
The Biotechnology Innovation Organization (BIO) has launched the "Fight of Our Lives" campaign, using real patient narratives to underscore the impact of American biotech. The initiative features three inaugural stories—a rare‑genetic condition treated with targeted gene therapy, the first CAR‑T...
Whitepaper: CDMOs at a Crossroads
The contract development and manufacturing organization (CDMO) sector is undergoing a rapid transformation as pharma and biotech firms chase end‑to‑end solutions for biologics, cell and gene therapies. Demand for specialized partnerships is rising alongside U.S. policies that encourage domestic production....
Obsidian, Galera to Advance Cell Therapy Following Reverse Merger
Obsidian Therapeutics will go public on Nasdaq via a reverse merger with Galera Therapeutics, creating a combined entity focused on OBX-115, a tumor‑infiltrating lymphocyte (TIL) cell therapy. OBX-115 is in mid‑stage melanoma and early‑stage lung‑cancer trials and is designed to...
BMS Makes a Beeline, Bringing 5 Assets to Biotech's $300M Precision Immunology Debut
Bristol Myers Squibb has spun out a new biotech, Beeline Medicines, backed by $300 million from Bain Capital and an initial portfolio of five assets. The company, led by former SpringWorks CEO Saqib Islam, will focus on precision therapies for autoimmune...
STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More
U.S. FDA has asked Eli Lilly to provide additional safety data on its newly approved obesity drug Foundayo, mandating post‑marketing trials for cardiovascular events, delayed gastric emptying, and a lactation study. The pill, a GLP‑1 agonist, received accelerated approval through the...
Eight Allergy Companies to Watch in 2026
The allergy‑treatment landscape is moving from symptom relief to disease‑modifying therapies, with eight biotech firms leading the charge in 2026. Allergy Therapeutics secured German approval for its short‑course Grassmuno vaccine, while Aravax bolstered its board ahead of a phase 3 launch...
Ads for GLP-1 Drugs Are Flooding the Internet – Here’s How to Know if It’s Safe to Buy Them Online
The surge in online advertisements for GLP‑1 weight‑loss drugs, amplified by a high‑profile Super Bowl commercial, has led many consumers to seek cheaper, compounded versions of medications like Ozempic and Wegovy. The FDA warns that these non‑brand products often bypass...
New Technique Maps Cancer Drug Uptake Inside Living Cells
Researchers at the University of Surrey and King's College London have unveiled a new analytical workflow that maps metal‑based cancer drugs inside living cells. By pairing SEISMIC capillary sampling with laser‑ablation ICP‑MS, they detected trace thallium—used as a surrogate for...
Australian Bee Glue Delivers a Scar-Fighting Compound that Shuts Down Raised Scars Before They Take Hold
University of the Sunshine Coast researchers have isolated a natural compound, tomentosenol A, from the propolis of the Australian stingless bee Tetragonula carbonaria. Laboratory tests on human skin cells showed the molecule blocks scar‑forming signals and induces fibroblast self‑destruction, mimicking normal...
ARS Pharmaceuticals Reports Health Canada Approval of Neffy 2mg to Treat Type I Allergic Reactions
Health Canada has approved ARS Pharma’s neffy 2 mg adrenaline nasal spray for adults and children weighing over 30 kg, marking the first needle‑free emergency treatment for anaphylaxis in the country. In November 2024, ARS granted ALK exclusive rights to commercialize neffy...
Will Cancer Drugmakers Ever Conquer P53?
Elephants’ 20 copies of the TP53 gene give them a powerful p53‑driven cancer shield, while humans rely on a single copy that is frequently mutated. Restoring p53 function has long been labeled “undruggable,” leading to a string of high‑profile failures,...
Takeda Continues to Prune Partnerships, Cuts Ties with mRNA-Targeting Veritas In Silico
Takeda announced the termination of its three‑year partnership with Veritas In Silico, a collaboration focused on small‑molecule drugs that target mRNA. The split, confirmed on April 13, follows a recent wave of collaborator cuts, including a break with Denali Therapeutics and...
TOBY Secures US FDA Breakthrough Device Designation for Urine-Based Multi-Cancer Test
TOBY has received FDA Breakthrough Device Designation for its urine‑based Multi‑Cancer Early Detection (MCED) test. The non‑invasive platform analyzes volatile organic compounds in a single urine sample using spectroscopy and machine‑learning algorithms to identify multiple cancer types. The designation positions...
Enhancing Oxidase‐Catalyzed Biosensing via Hydrophobic ZIF‐7 Nanomaterials: A Micro‐Triphase Interface Approach
The study introduces ZIF-7 nanoparticles as hydrophobic oxygen reservoirs in a solid–liquid–air triphase enzyme electrode, boosting oxidase‑catalyzed biosensing. By releasing pre‑stored O₂, the system raises Vmax 21‑fold and widens the glucose linear range from 2 mM to 20 mM, a ten‑fold improvement...
Bioadhesive Scaffold for Dual Delivery of Methotrexate‐Loaded Liposomes and Chondrogenic miRNA in Advanced Rheumatoid Arthritis Therapy
Researchers have engineered a bioadhesive scaffold that couples inflammation‑responsive methotrexate‑loaded liposomes with miRNA‑140‑bearing nanoparticles to treat advanced rheumatoid arthritis. The scaffold, composed of collagen, polydopamine‑modified hyaluronic acid and PEGDE cross‑linker, adheres to joint tissue, releases methotrexate when matrix metalloproteinases are...
Tumor Microenvironment‐Responsive Dual‐Enzymatic Flasklike Nanobots for Enhanced Chemotherapy
Researchers have engineered a flask‑shaped nanobot (GC‑M@FPNbot) that harnesses glucose oxidase and catalase to self‑propel in response to tumor‑specific proton and hydrogen peroxide gradients. Loaded with doxorubicin, the bots exhibit chemotactic motion that enables deep penetration of extracellular matrix and...
Multimodal Analysis of the Early Stage of Amyloid Formation via Graphene Liquid Cell Electron Microscopy
Researchers have combined graphene liquid‑cell transmission electron microscopy (GLC‑TEM) with semi‑ensemble and time‑sequential analyses to watch amyloid‑β oligomer formation in real time. The multimodal approach reveals that early‑stage aggregates exist in a kinetic quasi‑equilibrium, where rapid association‑dissociation events keep population...
STAT+: New Bain Biotech Startup, Building on BMS Drugs, Gets a Name and a CEO
Bain Capital Life Sciences has launched a new biotech venture, Beeline Medicines, backed by a $300 million investment and five drug assets licensed from Bristol Myers Squibb. The startup will focus on inflammatory and immune‑mediated diseases, beginning with an oral candidate for...
Danish MinervaX Bolsters Executive Team Amid Transition to Pivotal Vaccine Trial Phase
Denmark‑based biotech MinervaX has hired Jamila Louahed, a former GSK vaccine R&D executive, as Chief Development Officer and veteran life‑science CFO Hans Henrik Chrois Christensen. The leadership changes come as the company prepares to launch a pivotal Phase III trial...
QIAGEN Launches QIAstat-Dx BCID GPF Plus AMR Panel for Bloodstream Infection Syndromic Testing
QIAGEN has launched the CE‑IVDR‑certified QIAstat‑Dx BCID GPF Plus AMR Panel for rapid bloodstream‑infection syndromic testing. The assay detects 20 gram‑positive bacterial and fungal targets and ten antimicrobial‑resistance markers, delivering results in approximately one hour. Announced at the ESCMID Global...
